



**SDI FINAL EVALUATION FORM 1.1**

**PART 1:**

Journal Name:	<b>International Journal of Advances in Nephrology Research</b>
Manuscript Number:	<b>Ms_IJANR_119059</b>
Title of the Manuscript:	<b>Paradigm shift in Membranous nephropathy</b>
Type of Article:	<b>Original Research Article</b>

**PART 2:**

<b>FINAL EVALUATOR'S comments on revised paper (if any)</b>	<b>Authors' response to final evaluator's comments</b>
<p>1)Kindly revise the abstract and subdivide into introduction/aims/methodology/results and conclusion in a concise manner as per my previous comments.</p> <p>2)Clinical characteristics/comorbidities/creatinine and albumin in patients of pla2r positive and nell 1 should be expressed in table separately.</p> <p>3)The methodology is not detailed in terms of pathological processing and the techniques of immunostaining (PLA2R, NELL1, THSD7A).</p> <p>4)What treatment options as per kdigo were offered to the study patients at your centre besides rituximab? kindly subdivide patients as per the different treatment protocols.</p> <p>5)You can't talk about sub nephrotic proteinuria by urine dipstick which is a crude method and not the standard of care.</p> <p>6)The definition of remission mentioned in your methodology is incorrect as per KDIGO.</p> <p>7)What is the treatment resistance definition you adopted for the study considering membranous nephropathy is a lingering disease process.</p> <p>8) Was colonoscopy done and serum PSA done to rule out malignancy?</p> <p>9)Kindly correct grammatical errors and revert for further review. The authors have done a better job revising article, but it still has lot of scope for improvement</p>	

**Reviewer Details:**

Name:	<b>Gerry George Mathew</b>
Department, University & Country	<b>SRM Medical College Hospital and Research Centre, India</b>